Zivo Bioscience, Inc. (ZIVO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80K 160K 240K Q4 '20: 20K Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 4K Q3 '23: 15.8K Q4 '23: 27.6K Q1 '24: 63.4K Q2 '24: 59.3K Q3 '24: 79K Q4 '24: 157.2K Q1 '25: 121.5K Q2 '25: 174.9K Q3 '25: 209K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Gross Profit TTM

0 25K 50K 75K Q4 '22: 0 Q1 '23: 0 Q2 '23: 3.3K Q3 '23: 7.5K Q4 '23: 11.6K Q1 '24: 24.1K Q2 '24: 20.8K Q3 '24: 26.1K Q4 '24: 49K Q1 '25: 36.5K Q2 '25: 54.4K Q3 '25: 66.2K Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25

Operating Income TTM

-18M -12M -6M 0 6M 12M 18M Q4 '20: -8.6M Q1 '21: -8.2M Q2 '21: -9M Q3 '21: -7.3M Q4 '21: -8.8M Q1 '22: -8.7M Q2 '22: -9M Q3 '22: -9.4M Q4 '22: -8.7M Q1 '23: -8.7M Q2 '23: -8.4M Q3 '23: -8M Q4 '23: -7.3M Q1 '24: -6.6M Q2 '24: -13M Q3 '24: -13.7M Q4 '24: -13.4M Q1 '25: -16.3M Q2 '25: -9.7M Q3 '25: -8.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Net Income TTM

-18M -12M -6M 0 6M 12M 18M Q4 '20: -9.1M Q1 '21: -8.8M Q2 '21: -9.5M Q3 '21: -7.5M Q4 '21: -8.9M Q1 '22: -8.7M Q2 '22: -8.9M Q3 '22: -9.4M Q4 '22: -8.7M Q1 '23: -8.7M Q2 '23: -8.7M Q3 '23: -8.5M Q4 '23: -7.8M Q1 '24: -7.1M Q2 '24: -13.2M Q3 '24: -13.7M Q4 '24: -13.4M Q1 '25: -16.3M Q2 '25: -9.7M Q3 '25: -8.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Cost of Revenue TTM

0 50K 100K 150K Q4 '22: 0 Q1 '23: 0 Q2 '23: 701 Q3 '23: 8.4K Q4 '23: 16K Q1 '24: 39.3K Q2 '24: 38.6K Q3 '24: 52.9K Q4 '24: 108.3K Q1 '25: 85K Q2 '25: 120.5K Q3 '25: 142.8K Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25

Operating Cash Flow TTM

-9M -6M -3M 0 3M 6M 9M Q4 '20: -2.6M Q1 '21: -2.9M Q2 '21: -4.6M Q3 '21: -5.8M Q4 '21: -6.8M Q1 '22: -8.6M Q2 '22: -7.9M Q3 '22: -7.6M Q4 '22: -7.1M Q1 '23: -6.4M Q2 '23: -6M Q3 '23: -6.5M Q4 '23: -5.8M Q1 '24: -5.4M Q2 '24: -5M Q3 '24: -4.1M Q4 '24: -4.3M Q1 '25: -4M Q2 '25: -3.9M Q3 '25: -3.1M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Free Cash Flow TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q4 '11: -1.3M Q1 '12: -1.5M Q4 '12: -1.8M Q4 '11 Q1 '12 Q4 '12

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '10: 86.9M Q3 '10: 89.6M Q2 '11: 95.6M Q3 '11: 97.5M Q1 '13: 105.3M Q2 '13: 106.8M Q3 '13: 110.4M Q1 '14: 154M Q2 '14: 124.7M Q3 '14: 127.9M Q1 '15: 129.6M Q2 '15: 130.4M Q1 '24: 2.7M Q2 '24: 3M Q3 '24: 3.4M Q1 '25: 3.8M Q2 '25: 3.8M Q3 '25: 3.8M Q2 '11 Q2 '13 Q2 '14 Q2 '15 Q3 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '17: -0.07 Q1 '18: -0.09 Q2 '18: -0.10 Q3 '18: -0.11 Q4 '18: -0.09 Q1 '19: -0.08 Q2 '19: -0.07 Q3 '19: -0.05 Q4 '19: -0.05 Q1 '20: -0.04 Q2 '20: -0.26 Q3 '20: -0.94 Q4 '20: -0.02 Q1 '21: -0.02 Q2 '21: -0.07 Q3 '21: 0.41 Q4 '24: -4.28 Q1 '25: -4.93 Q2 '25: -2.58 Q3 '25: -2.18 Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.